Advertisement
Ocean Biomedical, Inc.

Ocean Biomedical, Inc. Fundamental Analysis

OCEAPNK
HealthcareBiotechnology
$0.00
$0.00(33.33%)
U.S. Market opens in 10h 58m
Advertisement

Ocean Biomedical, Inc. Fundamental Analysis

Ocean Biomedical, Inc. (OCEA) shows weak financial fundamentals with a PE ratio of -0.00, profit margin of 0.00%, and ROE of 8.38%. The company generates N/A in annual revenue with N/A year-over-year growth of N/A.

Key Strengths

PEG Ratio0.00

Areas of Concern

ROE8.38%
Operating Margin0.00%
Current Ratio0.06
We analyze OCEA's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of 36.9/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
36.9/100

We analyze OCEA's fundamental strength across five key dimensions:

Efficiency Score

Weak

OCEA struggles to generate sufficient returns from assets.

ROA > 10%
-5.03%

Valuation Score

Excellent

OCEA trades at attractive valuation levels.

PE < 25
-0.00
PEG Ratio < 2
0.00

Growth Score

Weak

OCEA faces weak or negative growth trends.

Revenue Growth > 5%
N/A
EPS Growth > 10%
N/A

Financial Health Score

Moderate

OCEA shows balanced financial health with some risks.

Debt/Equity < 1
-0.10
Current Ratio > 1
0.06

Profitability Score

Weak

OCEA struggles to sustain strong margins.

ROE > 15%
8.38%
Net Margin ≥ 15%
0.00%
Positive Free Cash Flow
No

Key Financial Metrics

Is OCEA Expensive or Cheap?

P/E Ratio

OCEA trades at -0.00 times earnings. This suggests potential undervaluation.

-0.00

PEG Ratio

When adjusting for growth, OCEA's PEG of 0.00 indicates potential undervaluation.

0.00

Price to Book

The market values Ocean Biomedical, Inc. at -0.00 times its book value. This may indicate undervaluation.

-0.00

EV/EBITDA

Enterprise value stands at 1.29 times EBITDA. This is generally considered low.

1.29

How Well Does OCEA Make Money?

Net Profit Margin

For every $100 in sales, Ocean Biomedical, Inc. keeps $0.00 as profit after all expenses.

0.00%

Operating Margin

Core operations generate 0.00 in profit for every $100 in revenue, before interest and taxes.

0.00%

ROE

Management delivers $8.38 in profit for every $100 of shareholder equity.

8.38%

ROA

Ocean Biomedical, Inc. generates $-5.03 in profit for every $100 in assets, demonstrating efficient asset deployment.

-5.03%

Following the Money - Real Cash Generation

FCF Per Share

Each share generates $-0.10 in free cash annually.

$-0.10

FCF Yield

OCEA converts -24.24% of its market value into free cash.

-24.24%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-0.00

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

0.00

vs 25 benchmark

P/B Ratio

Price to book value ratio

-0.00

vs 25 benchmark

P/S Ratio

Price to sales ratio

0.00

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

-0.10

vs 25 benchmark

Current Ratio

Current assets to current liabilities

0.06

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

0.08

vs 25 benchmark

ROA

Return on assets percentage

-5.03

vs 25 benchmark

ROCE

Return on capital employed

-0.04

vs 25 benchmark

How OCEA Stacks Against Its Sector Peers

MetricOCEA ValueSector AveragePerformance
P/E Ratio-0.0029.03 Better (Cheaper)
ROE8.38%773.00% Weak
Net Margin0.00%-53616.00% (disorted) Weak
Debt/Equity-0.100.50 Strong (Low Leverage)
Current Ratio0.064.44 Weak Liquidity
ROA-502.97%-20231.00% (disorted) Weak

OCEA outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Ocean Biomedical, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

N/A

Industry Style: Defensive, Growth, Innovation

EPS CAGR

N/A

Industry Style: Defensive, Growth, Innovation

FCF CAGR

N/A

Industry Style: Defensive, Growth, Innovation

Fundamental Analysis FAQ